Zhejiang Hospital Pharmacy Administration Quality Control Center, Hospital Pharmacy Committee of Zhejiang Pharmaceutical Association, Microbial Resistance and Control Committee of Zhejiang Pharmaceutical Association, Bacterial Infections and Antibiotic Resistance Prevention Committee of Zhejiang Medical Association, First Affiliated Hospital, Zhejiang University School of Medicine. Clinical Guidelines for the Use of Ceftazidime-Avibactam[J]. Chinese Journal of Modern Applied Pharmacy, 2025, 42(13): 2348-2358. DOI: 10.13748/j.cnki.issn1007-7693.20250174
    Citation: Zhejiang Hospital Pharmacy Administration Quality Control Center, Hospital Pharmacy Committee of Zhejiang Pharmaceutical Association, Microbial Resistance and Control Committee of Zhejiang Pharmaceutical Association, Bacterial Infections and Antibiotic Resistance Prevention Committee of Zhejiang Medical Association, First Affiliated Hospital, Zhejiang University School of Medicine. Clinical Guidelines for the Use of Ceftazidime-Avibactam[J]. Chinese Journal of Modern Applied Pharmacy, 2025, 42(13): 2348-2358. DOI: 10.13748/j.cnki.issn1007-7693.20250174
    • OBJECTIVE  To standardize the clinical rational use of ceftazidime-avibactam in the treatment of multidrug-resistant Gram-negative bacterial infections and provide scientific guidance for clinical practice.
      METHODS  The Zhejiang Hospital Pharmacy Administration Quality Control Center, Hospital Pharmacy Committee of Zhejiang Pharmaceutical Association, Microbial Resistance and Control Committee of Zhejiang Pharmaceutical Association, Bacterial Infections and Antibiotic Resistance Prevention Committee of Zhejiang Medical Association organized an expert team in the fields of clinical pharmacy, infectious diseases, and microbiology. Based on evidence-based medical evidence and expert opinions, and after multiple rounds of expert discussions, a clinical medication guide for ceftazidime-avibactam was developed.
      RESULTS  The guide includes 13 clinical questions and 28 recommendations, covering aspects such as indications, antimicrobial spectrum, dosage and administration, use in special populations, therapeutic drug monitoring, and clinical management of ceftazidime-avibactam.
      CONCLUSION  The guidelines can provide scientific guidance for the rational use of ceftazidime-avibactam by clinicians, and improve the treatment outcomes of multidrug-resistant Gram-negative bacterial infections.
    • loading

    Catalog

      Turn off MathJax
      Article Contents

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return